Cardiovascular effects of endomorphins in alloxan-induced diabetic rats. 2005

Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
Department of Biochemistry and Molecular Biology, School of Life Sciences, Lanzhou University, 222 Tian Shui South Road, Lanzhou 730000, PR China.

Endomorphins, the endogenous, potent and selective mu-opioid receptor agonists, have been shown to decrease systemic arterial pressure (SAP) in rats. In the present study, responses to endomorphins were investigated in systemic vascular bed of alloxan-induced diabetic rats and in non-diabetic rats. Diabetes was induced by alloxan (220 mg/kg, i.p.) in male Wistar rats. At 4-5 weeks after the onset of diabetes, intravenous injections of endomorphins (1-30 nmol/kg) led to an increase of SAP and heart rate (HR) consistently and dosed-dependently. SAP increased 7.68+/-3.73, 11.19+/-4.55, 21.19+/-2.94 and 27.48+/-6.21% from the baseline at the 1, 3, 10 and 30 nmol/kg dose, respectively, of endomorphin 1 (n=4; p<0.05), and similar changes were observed in response to endomorphin 2. The hypertension could be antagonized markedly by i.p. 2 mg/kg of naloxone. On the other hand, bilateral vagotomy would attenuate the effects of hypertension and diminished the changes of HR in response to endomorphins. With diabetic rats, 6-10 weeks after the induction of diabetes, intravenous injections of endomorphins produced non-dose-related various changes in SAP, such as a single decrease, or a single increase, or biphasic changes characterized by an initial decrease followed by a secondary increase, or no change at all. These results suggest that diabetes may lead to the dysfunction of the cardiovascular system in response to endomorphins. Furthermore, the diabetic rats of 4-5 weeks after alloxan-treatment, the increase in SAP and HR caused by i.v. endomorphins might be explained by a changed effect of vagus and by a naloxone-sensitive mechanism.

UI MeSH Term Description Entries
D008297 Male Males
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014628 Vagotomy The interruption or removal of any part of the vagus (10th cranial) nerve. Vagotomy may be performed for research or for therapeutic purposes. Vagotomies

Related Publications

Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
January 2014, EXCLI journal,
Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
November 2008, Acta oto-laryngologica,
Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
January 2012, Recent patents on endocrine, metabolic & immune drug discovery,
Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
May 2008, Phytotherapy research : PTR,
Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
November 2020, Pakistan journal of pharmaceutical sciences,
Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
December 2022, Iranian journal of pharmaceutical research : IJPR,
Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
February 2008, Singapore medical journal,
Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
April 2010, Journal of ethnopharmacology,
Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
April 1985, Proceedings of the National Science Council, Republic of China. Part B, Life sciences,
Jing Liu, and Ye Yu, and Ying-zhe Fan, and Hui Chang, and Hong-mei Liu, and Yun Cui, and Qiang Chen, and Rui Wang
August 2002, Pharmacological research,
Copied contents to your clipboard!